YOUR SEARCH FOR Text 262 RESULTS
41 of Total
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativ
View all news Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of
42 of Total
Incyte to Report First Quarter Financial Results | Incyte
View all news Incyte to Report First Quarter Financial Results April 9, 2026 at 8:00 AM EDT PDF Version WILMINGTON, Del. --(BUSINESS WIRE)--Apr. 9,
43 of Total
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results | Incyte
View all news Incyte Reports Fourth Quarter and Full Year 2025 Financial Results February 10, 2026 at 7:00 AM EST PDF Version Total revenue of $1.51
44 of Total
Media Contact | Incyte
Name Email Subject Comments Leave this field blank For Media Inquiries media@incyte.com
45 of Total
Press Releases | Incyte
The information contained in press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to
46 of Total
Resources | Incyte
Investor Email Alerts RSS Feeds Investor FAQs Subscribe to Email Alerts To opt-in for investor email alerts, please enter your email address in the
47 of Total
Stock information | Incyte
Stock Quote & Chart Historical Lookup Analyst Coverage Stock Quote Change Volume Today's Open Previous Close Today's High Today's
48 of Total
Incyte Stories from Researchers and Scientists | Incyte.com
Innovation with the Incyte Ingenuity Awards . View Story Our Global Responsibility: By the Numbers . View Story Incyte Gets Involved . View Story
49 of Total
Incyte Stories from Researchers and Scientists | Incyte.com
Understanding Hidradenitis Suppurativa (HS) . View Story The Science Within the Skin . View Story Understanding DLBCL . View Story Solve On . Stories
50 of Total
2023 Year in Review | Incyte Stories
February 1, 2024 2023: How We Continue to Solve On . For Patients In 2023, we progressed our mission to Solve On . for patients around the world and